AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Flagship Ventures Names Daniel McIntyre Partner

Flagship Ventures Names Daniel McIntyre Partner

June 29, 2016

Industry Veteran Assumes new position to lead strategic communication

CAMBRIDGE, Mass., June 29, 2016 -- Flagship Ventures today announced the appointment of Daniel McIntyre to the position of Partner, Strategic Communication. In this new role, he is responsible for communication for Flagship's growing organization as well as for its expanding ecosystem of internally generated start-up companies.

Evelo Biosciences and Epiva Biosciences Merge to Create the Leading Immuno-Microbiome Platform Company

Evelo Biosciences and Epiva Biosciences Merge to Create the Leading Immuno-Microbiome Platform Company

July 12, 2016

Company will focus on next generation immunotherapies for cancer, autoimmune and inflammatory diseases

Noubar Afeyan, Ph.D., Appointed Chairman; Executive Leadership Team Expanded

Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer

Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer

July 13, 2016

Cambridge, Mass., July 13, 2016 (PR Newswire) – Flagship Ventures today announced the appointment of industry veteran Michael Rosenblatt, M.D., to the new position of Chief Medical Officer. In this capacity, Dr. Rosenblatt will lead global clinical development and medical affairs for the organization.

Syros Pharmaceuticals Announces Pricing of Initial Public Offering

Syros Pharmaceuticals Announces Pricing of Initial Public Offering

June 29, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $12.50 per share, before underwriting discounts and commissions. In addition, Syros has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Syros at the public offering price, less the underwriting discount and commissions, to cover over-allotments, if any. All of the shares are being offered by Syros Pharmaceuticals.

Selecta Biosciences Announces Pricing of Initial Public Offering

Selecta Biosciences Announces Pricing of Initial Public Offering

June 21, 2016

WATERTOWN, Mass., (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Selecta Biosciences.

Axcella to Present at the JMP Securities Life Sciences Conference

Axcella to Present at the JMP Securities Life Sciences Conference

June 15, 2016

CAMBRIDGE, Mass., – Axcella Health Inc., a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the JMP Securities Life Sciences Conference in New York, N.Y. The presentation will take place June 22, 2016, at 3 p.m. EDT.

About Axcella Health

Axcella to Present at Jefferies 2016 Healthcare Conference

Axcella to Present at Jefferies 2016 Healthcare Conference

June 8, 2016

CAMBRIDGE, Mass., – Axcella Health Inc., a biotechnology company pioneering transformative medicines for patients with conditions where disrupted amino acid biology plays a critical role, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference in New York, N.Y. The presentation will take place June 9, 2016, at 9 a.m. EDT.

About Axcella Health

Pronutria Biosciences Rebrands as Axcella Health

Pronutria Biosciences Rebrands as Axcella Health

June 7, 2016

Company Unveils Clinical Programs Across Three Disease Categories

CAMBRIDGE, Mass. – Pronutria Biosciences today announced that it has changed its corporate name to Axcella Health to better reflect its mission of harnessing amino acids for cell health through a systems pharmacology approach. The company uses oral protein biologics to precisely deliver disease-specific amino acid profiles that have systems-wide effects, which restore cell homeostasis and address underlying disease conditions.